Development and Validation of a HILIC–HPLC Method for the Quantitative Determination of Favipiravir in Tablet Formulations
Pharmata · 2025
DOI: 10.62425/pharmata.1759097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmata, 2025. Verfasst von Dilhe Nur Çim Tunçer. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objective
A validated Hydrophilic Interaction Liquid Chromatography (HILIC) method was developed for the quantitative determination of Favipiravir.
Methods
The chromatographic analysis was performed using a high-performance liquid chromatography (HPLC) system comprising a diode array detector, vacuum pump, column thermostat, and autosampler (Agilent 1260, Agilent Technologies, Santa Clara, CA, USA). The analysis was conducted on a ZORBAX RRHD HILIC Plus analytical column (95 Å, 2.1 × 150 mm, 1.8 µm). The mobile phase consisted of acetonitrile and water (80:20, v/v). Chromatographic separation was achieved under isocratic elution at a flow rate of 0.8 mL/min, and Favipiravir was detected at a wavelength of 322 nm.
Results
The retention time of Favipiravir was 1.8317 ± 0.002 min, with a limit of detection (LOD) of 0.14 μg/mL and a limit of quantification (LOQ) of 0.47 μg/mL. The regression equation was y = 107.54x + 17.034 with a correlation coefficient (r²) of 0.9997.
Conclusion
The proposed method was validated in terms of specificity, linearity, accuracy, precision, LOD, and LOQ, and was successfully applied for the quantitative analysis of Favipiravir in tablet formulations.
Zitieren
APA
Tunçer, D. N. Ç. (2025). Development and Validation of a HILIC–HPLC Method for the Quantitative Determination of Favipiravir in Tablet Formulations. Pharmata. https://doi.org/10.62425/pharmata.1759097
Vancouver
Tunçer DNÇ. Development and Validation of a HILIC–HPLC Method for the Quantitative Determination of Favipiravir in Tablet Formulations. Pharmata. 2025. doi:10.62425/pharmata.1759097
BibTeX
@article{Tuner2025,
author = {Tunçer, Dilhe Nur Çim},
title = {Development and Validation of a HILIC–HPLC Method for the Quantitative Determination of Favipiravir in Tablet Formulations},
journal = {Pharmata},
year = {2025},
doi = {10.62425/pharmata.1759097}
}
EUVIMED